An announcement from Brii Biosciences Limited ( (HK:2137) ) is now available.
Brii Biosciences Limited announced its annual results for 2024, highlighting a strategic focus on its hepatitis B virus (HBV) functional cure program. Despite a decrease in cash reserves and an increased loss for the year, the company made significant progress in its clinical trials, particularly with its leading HBV therapeutic candidates, BRII-179, elebsiran, and tobevibart. These candidates have received Breakthrough Therapy Designation, and the company has acquired full intellectual property rights for BRII-179, enhancing its commercial potential. Brii Bio’s strategic investments in its discovery pipeline and organizational optimization reflect its commitment to advancing research and delivering innovative healthcare solutions.
More about Brii Biosciences Limited
Brii Biosciences Limited is a biotechnology company focused on developing innovative therapies for infectious diseases. The company is particularly concentrated on creating functional cures for hepatitis B virus (HBV), with additional interests in treatments for HIV and multi-drug resistant infections. Brii Bio’s market focus includes leveraging partnerships and advancing clinical trials to bring cutting-edge solutions to patients globally.
YTD Price Performance: 156.67%
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €233M
See more insights into 2137 stock on TipRanks’ Stock Analysis page.